Despite declining economic trends, successful Biotech and Medical Device
companies continue to enjoy healthy demand in established and emerging
product lines and markets. Indeed, some are pushing successfully into new
areas, focusing on patients needs and bringing outcomes-centric healthcare
products and services to the market. In the long run, global demographics
and socio-economic trends point to increasing world wide demand for
healthcare products. Rapidly rising costs will help fuel the adoption of
innovative and efficient healthcare products and technologies.
Within
this context, all healthcare executives must respond to threatening changes
in their markets and consider the long-term impact of economic disruptions.
These uncertain times demand that all companies adopt restrained spending
and improved efficiencies, even while trying to expand market share and
maintain profitability. Today, there are no biotech or device companies that
can delay evaluating and revising spending patterns throughout their
organizations.
This panel
will review recent trends in cost-cutting and cost based transformation in
this industry.
A particular focus will be placed
on
discussing new industry trends and leading practices, sharing case studies
for Customer Service and Project Portfolio Management, with critical
implications for the Life-Sciences as well as High-Tech sectors.
Our speakers will share their experiences and we will discuss
some examples of how industry leaders are navigating in tougher times while
staying focused on winning the race.
Breakfast will be served!
Our Panel of Experts:
Sandi Hassett
Director, US Customer
Service, Johnson & Johnson (J&J)
Case study on Patient
Relationship Management Domains
Peter
Barschdorff
PhD, Senior Manager, Life Sciences Practice, Capgemini
Medical Devices
survey on Costs Transformation
Peter
is a trusted industry advisor and a senior member of the Capgemini
North America Life Sciences practice. He has been directing some of
the most critical strategy engagements for key Pharmaceutical and
Medical Devices accounts of the Fortune 500 companies’ index, with a
focus on Sales and Marketing and Commercial Operations. Most recently,
Peter helped a specialty pharmaceuticals manufacturer devise a new
global franchise strategy. He has also developed a new pricing
approach for the largest Strategic Business Unit of a U.S.-based, top
medical device company, and he has guided several organizational
change initiatives in the technology space. On the innovation side,
Peter has been growing and leading the Medical Device and Diagnostics
offerings, network and community across geographies. Peter has been
recognized for his contribution to various industry research and
surveys conducted on a global basis, such as Capgemini’s yearly Life
Sciences publication: “Vision & Reality”. Peter has authored several
though leadership publications, most recently "Medical Devices and
Diagnostics: The Need for Dual Focus on the Top Line and Bottom Line."
Peter started is career in Germany and has been serving U.S. Life
Sciences clients for ten years. He holds a MBA from Columbia Business
School and a Ph.D. from the Free University (Berlin, Germany).
Antoine VillataDirector of Professional Services, Planisware
Project Portfolio Management Antoine
is Director of professional services at Planisware USA – a leading
global Corporate Portfolio Management software company supplying
solutions to companies managing complex R&D investments. After working
a few years in the company headquarters in Paris, Antoine moved to the
US in 2001 to lead the development of Planisware services in North
America, setting up operations in both San Francisco (CA) and Trenton
(NJ). He has over 10 years of extensive hands-on experience in the
field of project and portfolio management (PPM) both in the US and in
Europe. His experience includes the design and the implementation of
PPM solutions at several major Life Sciences and High Tech companies.
He has directed multi-site and multi region projects partnering with
large consulting firms to implement recognized processes and
methodologies aimed at increasing the returns on R&D investments.
Before joining Planisware, Antoine worked for 2 years in Hanoi,
Vietnam as a Trade Attaché for the French embassy. Antoine received a
MS in Innovation Management from Compiegne Technology University in
France and he is in the second year of the Executive MBA Program at
the Wharton Business School.
Fred
Dorey
Special Counsel, Life Sciences Practice Group, Cooley Godward Kronish
Moderator Special
Counsel with the law firm of Cooley Godward Kronish, Fred represents a
range of biotechnology, instrumentation and "clean" technology
companies at various stages of development from start-up and
incorporation through licensing, corporate partnering and
collaboration transactions. He also has experience negotiating
clinical trial, sponsored research and intellectual property
agreements. In addition, Mr. Dorey advises a number of major
foundations, research institutions, and individuals regarding their
participation in biomedical research endeavors, including investment,
licensing and commercialization. Before joining Cooley, Mr. Dorey was
the first president of the Bay Area Bioscience Center (now BayBio), a
consortium of research universities, biotechnology companies and local
governments organized to support bioscience development in Northern
California. He also served as part-time in-house counsel for several
biotech companies including Tularik, Geron and Shaman. Previously, he
had served as general counsel and corporate secretary for BP in San
Francisco, where he was chief legal advisor for the Fortune 500-sized
subsidiary that handled all BP oil exploration and production in the
US.. He has also served as a regulatory enforcement lawyer and
assistant office director for the Department of Energy in DC.
Registrations
$30 at the door
Cancellations must be made 5-days prior to the event date
Any cancellation within a 5-day period of the scheduled date will not
be refunded
Name of guests will be kept at the door
The French-American Chamber of Commerce of San Francisco thanks its first
Benefactor Member:
Barclais USA
________________________________________
French-American Chamber of Commerce
703 Market Street, Suite 450, San Francisco, CA
94103
Peter
is a trusted industry advisor and a senior member of the Capgemini
North America Life Sciences practice. He has been directing some of
the most critical strategy engagements for key Pharmaceutical and
Medical Devices accounts of the Fortune 500 companies’ index, with a
focus on Sales and Marketing and Commercial Operations. Most recently,
Peter helped a specialty pharmaceuticals manufacturer devise a new
global franchise strategy. He has also developed a new pricing
approach for the largest Strategic Business Unit of a U.S.-based, top
medical device company, and he has guided several organizational
change initiatives in the technology space. On the innovation side,
Peter has been growing and leading the Medical Device and Diagnostics
offerings, network and community across geographies. Peter has been
recognized for his contribution to various industry research and
surveys conducted on a global basis, such as Capgemini’s yearly Life
Sciences publication: “Vision & Reality”. Peter has authored several
though leadership publications, most recently "Medical Devices and
Diagnostics: The Need for Dual Focus on the Top Line and Bottom Line."
Peter started is career in Germany and has been serving U.S. Life
Sciences clients for ten years. He holds a MBA from Columbia Business
School and a Ph.D. from the Free University (Berlin, Germany).
Special
Counsel with the law firm of Cooley Godward Kronish, Fred represents a
range of biotechnology, instrumentation and "clean" technology
companies at various stages of development from start-up and
incorporation through licensing, corporate partnering and
collaboration transactions. He also has experience negotiating
clinical trial, sponsored research and intellectual property
agreements. In addition, Mr. Dorey advises a number of major
foundations, research institutions, and individuals regarding their
participation in biomedical research endeavors, including investment,
licensing and commercialization. Before joining Cooley, Mr. Dorey was
the first president of the Bay Area Bioscience Center (now BayBio), a
consortium of research universities, biotechnology companies and local
governments organized to support bioscience development in Northern
California. He also served as part-time in-house counsel for several
biotech companies including Tularik, Geron and Shaman. Previously, he
had served as general counsel and corporate secretary for BP in San
Francisco, where he was chief legal advisor for the Fortune 500-sized
subsidiary that handled all BP oil exploration and production in the
US.. He has also served as a regulatory enforcement lawyer and
assistant office director for the Department of Energy in DC.